Vireo Growth (VREOF) Intangibles (2020 - 2026)
Vireo Growth (VREOF) reported Intangibles of $78.7 million for Q1 2026, up 922.81% on a YoY basis from $7.7 million in Q1 2025, and down 30.48% sequentially from $113.2 million in Q4 2025.
Vireo Growth (VREOF) Intangibles (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Intangibles data on file, last reported at $78.7 million in Q1 2026.
- For the quarter ending Q1 2026, Intangibles rose 922.81% year-over-year to $78.7 million; the trailing twelve-month figure through Mar 2026 stood at $78.7 million (up 922.81% YoY), and the FY2025 full-year result was $113.2 million, up 1332.91% from the prior year.
- Intangibles retreated to $78.7 million in Q1 2026, from $113.2 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $113.2 million in Q4 2025 to a low of $7.7 million in Q1 2025.
- A 5-year average of $27.4 million and a median of $8.8 million in 2022 frame the typical range for Intangibles.
- Across the five-year window, Intangibles dropped 17.63% in 2023 and surged 1332.91% in 2025, its largest moves.
- Tracing VREOF's Intangibles over 5 years: stood at $8.8 million in 2022, then fell by 0.67% to $8.7 million in 2023, then dropped by 9.39% to $7.9 million in 2024, then surged by 1332.91% to $113.2 million in 2025, then sank by 30.48% to $78.7 million in 2026.
- Business Quant data shows VREOF's Intangibles at $78.7 million in Q1 2026, $113.2 million in Q4 2025, and $83.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 34.07 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.61 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 959.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 21.80 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 473.93 Mn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.48 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.23 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 78.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 78.70 Mn |
| Dec 31, 2025 | 113.20 Mn |
| Sep 30, 2025 | 83.18 Mn |
| Jun 30, 2025 | 79.21 Mn |
| Mar 31, 2025 | 7.69 Mn |
| Dec 31, 2024 | 7.90 Mn |
| Sep 30, 2024 | 8.10 Mn |
| Jun 30, 2024 | 8.31 Mn |
| Mar 31, 2024 | 8.51 Mn |
| Dec 31, 2023 | 8.72 Mn |
| Sep 30, 2023 | 8.94 Mn |
| Jun 30, 2023 | 8.05 Mn |
| Mar 31, 2023 | 8.62 Mn |
| Dec 31, 2022 | 8.78 Mn |
| Sep 30, 2022 | 8.94 Mn |
| Jun 30, 2022 | 9.77 Mn |
| Mar 31, 2022 | 9.94 Mn |
| Dec 31, 2021 | 10.18 Mn |
| Sep 30, 2021 | 5.42 Mn |
| Jun 30, 2021 | 3.19 Mn |